Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD

  • 0 views
  • 29 Jan, 2021
  • 14 locations
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has

  • 0 views
  • 28 Jan, 2021
  • 9 locations
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: To determine

mantle cell lymphoma
anti-cd20 monoclonal antibody
ct scan
measurable disease
chronic lymphocytic leukemia
  • 116 views
  • 27 Jan, 2021
  • 22 locations
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic

leucovorin
mercaptopurine oral suspension
prednisone
methotrexate
lymphoblastic lymphoma
  • 84 views
  • 03 Mar, 2021
  • 118 locations
A Study of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Acute Lymphoblastic Leukemia (ALL)

The primary objectives of this study are to evaluate the safety and tolerability of blinatumomab in combination with AMG 404 in adults with acute lymphoblastic leukemia (ALL) and to estimate the

blinatumomab
dexamethasone
lymphoid leukemia
  • 0 views
  • 02 Mar, 2021
  • 12 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

diagnostics, but above all, qualitatively reorient the therapy. The most important consequence will be that this study is testing immunotherapy with the bispecific antibody blinatumomab as an alternative to

methotrexate
residual tumor
fludarabine
daunorubicin
pegaspargase
  • 562 views
  • 26 Jan, 2021
  • 168 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Remission Induction, by the addition of molecular and immunotherapeutic approaches including tyrosine kinase inhibitors or chimeric antigen receptor (CAR) T cell / blinatumomab for refractory B-acute

vorinostat
idarubicin
methotrexate
residual tumor
lymphoblastic lymphoma
  • 230 views
  • 29 Jan, 2021
  • 7 locations
A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised …

imatinib
inotuzumab
vincristine
dexamethasone
doxorubicin
  • 27 views
  • 27 Jan, 2021
  • 102 locations
Blinatumomab Bridging Therapy

The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT

  • 0 views
  • 03 Feb, 2021
  • 1 location
Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B

bosutinib
tyrosine
renal function
ponatinib
imatinib
  • 6 views
  • 23 Jan, 2021
  • 2 locations